Why Edwards Lifesciences Corporation (EW) stock moved
Edwards Lifesciences Corporation (EW) shares fell 0.0% to $85.15 as of October 4, 2026, a slight decline from the prior close of $85.19. BestStocks flagged the session as a major change for EW. The move is tied to company news. Below, we break down what changed for EW, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Edwards Lifesciences receives FDA approval for AUTUS, first surgical pulmonary valve for pediatric patients. Expands EW's pediatric cardiac portfolio, addressing unmet need and opening new revenue stream in growing segment.
What it means for Edwards Lifesciences Corporation investors
For Edwards Lifesciences Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Edwards Lifesciences reported Q1 2026 revenue of $1.65B, up 12.7% year-over-year and beating consensus estimates of $1.6B; adjusted EPS of $0.78 exceeded forecast of $0.73 by 6.85%. Weighing against that: Material negative event; Negative session, down 0.0%. Wall Street's consensus price target sits at $101.70, implying +19.4% upside from $85.15. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (30/100). With earnings roughly 25 days out, the next report is the most likely near-term test of the move.
EW price reaction
EW last traded at $85.15, down $0.04 (-0.05%) from the previous close of $85.19. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $84.37 and $89.90, and it currently sits about 14% of the way up that band.
Bullish and bearish analyst opinions on Edwards Lifesciences Corporation (EW)
The consensus analyst price target on Edwards Lifesciences Corporation (EW) is $101.70, 19.4% above the recent $85.15. Over the past 90 days analysts logged 1 upgrade, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on EW line up.
The bullish case
- Wall Street's consensus price target of $101.70 implies +19.4% upside from $85.15.
- The Street's most bullish target is $110.00 (+29.2%).
- 1 analyst upgrade in the past 90 days, most recently Leerink Partners to Outperform (2026-07-24).
- Positive price momentum.
- Edwards Lifesciences reported Q1 2026 revenue of $1.65B, up 12.7% year-over-year and beating consensus estimates of $1.6B; adjusted EPS of $0.78 exceeded forecast of $0.73 by 6.85%.
The bearish case
- The most bearish analyst target is $85.00 (-0.2%).
- Material negative event.
- Negative session, down 0.0%.
- Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified.
- Edwards Lifesciences Corporation (EW) moved -3.13% from $90.09 to $87.27 on 2026-07-15.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 4, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for EW
Frequently asked questions about EW
Why did Edwards Lifesciences Corporation (EW) stock move?
EW fell 0.0% to $85.15. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did EW stock fall?
EW lost 0.05% ($0.04) versus the prior close of $85.19, last trading at $85.15 on 0.6× average volume.
When is Edwards Lifesciences Corporation's next earnings date?
EW's next earnings report is estimated for 2026-10-29 — about 25 days away.
What is the analyst price target for EW?
The consensus analyst price target for EW is $101.70, about 19.4% above the current $85.15. Over the past 90 days, analysts recorded 1 upgrade, 8 maintains, and 0 downgrades.
How BestStocks tracks EW
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for EW, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.